Hansen Gwenn — SEC Form 4 filings
SEC reporting owner CIK 1817160. 20 Form 4 filings on record with FilingPulse; latest filed 2026-09-01.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-01-30 to 2026-09-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 18 legs across 15 filings — 53,917 shares, $991,539 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 81.
- Largest priced transaction: sale of 4,356 shares @ $25.00 ($108,900) in Nurix Therapeutics, Inc., filed 2026-08-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | Chief Scientific Officer | 20 | — | 18 legs · 53,917 sh · $991,539 | 81 |
Form 4 filings — Hansen Gwenn
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 1,452 @ $1.86 · Sale (S): 1,452 @ $25.47 · Option exercise (M): 1,452 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Nurix Therapeutics, Inc. (NRIX) | Sale (S): 1,500 @ $23.87 · Sale (S): 2,611 @ $24.64 | EDGAR |
| 2026-08-05 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 4,356 @ $1.86 · Sale (S): 4,356 @ $25 · Option exercise (M): 4,356 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Option exercise (M): 3,572 @ $0 · Sale (S): 3,847 @ $23.38 · Option exercise (M): 3,750 (derivative) @ $0 · Option exercise (M): 2,858 (derivative) @ $0 · +1 more | EDGAR |
| 2026-06-25 | 4 | Nurix Therapeutics, Inc. (NRIX) | Sale (S): 5,394 @ $20 | EDGAR |
| 2026-04-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 3,214 @ $16.65 · Option exercise (M): 2,000 (derivative) @ $0 · Option exercise (M): 3,750 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-10 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 93,750 (derivative) @ $0 · Grant/award (A): 42,875 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 31,333 @ $0.84 · Option exercise (M): 31,333 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,859 @ $0 · Sale (S): 4,797 @ $16.58 · Sale (S): 98 @ $17.37 · +4 more | EDGAR |
| 2025-10-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 4,087 @ $12.80 · Option exercise (M): 3,207 (derivative) @ $0 · +3 more | EDGAR |
| 2025-10-23 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 4,308 @ $12.01 · Option exercise (M): 3,207 (derivative) @ $0 · +3 more | EDGAR |
| 2025-04-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,206 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Sale (S): 3,377 @ $11.50 · Option exercise (M): 3,206 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 · +1 more | EDGAR |
| 2025-02-13 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 75,000 (derivative) @ $0 · Grant/award (A): 34,300 (derivative) @ $0 | EDGAR |
| 2025-01-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Sale (S): 3,357 @ $19.81 · Sale (S): 333 @ $20.33 · Option exercise (M): 3,207 (derivative) @ $0 · +2 more | EDGAR |
| 2024-10-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Sale (S): 3,437 @ $24.30 · Option exercise (M): 3,207 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 · +1 more | EDGAR |
| 2024-07-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Sale (S): 3,408 @ $20.67 · Option exercise (M): 3,207 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 · +1 more | EDGAR |
| 2024-04-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,206 @ $0 · Option exercise (M): 2,000 @ $0 · Sale (S): 2,007 @ $12.04 · Option exercise (M): 3,206 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-01-30 | 4 | Nurix Therapeutics, Inc. (NRIX) | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Sale (S): 2,334 @ $7.99 · Option exercise (M): 3,207 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1817160 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →